Osimertinib as First-Line Therapy of Patients with Lung Adenocarcinoma EGFR TKI Mutation from Pleural Fluid Samples: A Case Report

Introduction: Lung cancer is still a major contributor to cancer mortality worldwide. More than 80–85% of cases are constituted by Non-Small Cell Lung Cancer (NSCLC), consisting of approximately 40% adenocarcinomas. The prevalence of T790M mutation also accounts for 30%–50% of resistance to first- a...

Descripción completa

Detalles Bibliográficos

Autores principales:	Harry Akza Putrawan, Arif Santoso, Nur Zam Zam, Irma Fitriani, Zainul Muttaqin
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Dharmais Cancer Hospital - National Cancer Center 2023-09-01
Colección:	Indonesian Journal of Cancer
Materias:	egfr tki mutation lung adenocarcinoma osimertinib pleural fluid samples
Acceso en línea:	https://www.indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/993
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!